Literature DB >> 6865923

The relationship between increases in the hepatic content of cytochrome P-450, form 5, and in the metabolism of aromatic amines to mutagenic products following treatment of rabbits with phenobarbital.

I G Robertson, C Serabjit-Singh, J E Croft, R M Philpot.   

Abstract

Treatment of rabbits with phenobarbital is followed by increases in the hepatic microsomal concentration of cytochrome P-450, form 5, and in the hepatic microsomal metabolism of aromatic amines to mutagenic products. Inhibition by antibodies to form 5 of the activation of 2-aminoanthracene and 2-aminofluorene demonstrates that these increases are directly related. The extent of the apparent induction of form 5 by phenobarbital is determined from single radial immunodiffusion, immunostaining of form 5 on nitrocellulose sheets containing microsomal proteins transferred from polyacrylamide gels, and the amount of antibody required for 50% of maximal inhibition of activity. The results indicate that phenobarbital increases the hepatic microsomal concentration of cytochrome P-450, form 5, to the same extent that it increases form 5-mediated metabolism of aromatic amines to mutagenic products: 10- to 12-fold. In contrast to the effects of phenobarbital, treatment of rabbits with beta-naphthoflavone decreases the hepatic microsomal concentration of cytochrome P-450, form 5, to less than detectable levels and has little effect on the metabolism of aromatic amines to mutagenic products. Our findings, along with the known effects of phenobarbital on cytochrome P-450, form 2, and the known catalytic activity of cytochrome P-450, form 4, lead to the following conclusions: (a) treatment of rabbits with phenobarbital results in increases in the hepatic microsomal concentrations of at least two structurally, immunochemically, and catalytically distinct isozymes of cytochrome P-450, forms 2 and 5; (b) the metabolism of aromatic amines to mutagenic products in rabbit hepatic microsomal preparations depends on the relative concentrations of at least two isozymes of cytochrome P-450, forms 4 and 5, that change in response to different inducers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6865923

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016.

Authors:  O T Parkinson; E J Kelly; E Bezabih; D Whittington; A E Rettie
Journal:  J Vet Pharmacol Ther       Date:  2011-09-15       Impact factor: 1.786

2.  Ligand characterization of CYP4B1 isoforms modified for high-level expression in Escherichia coli and HepG2 cells.

Authors:  Katharina Roellecke; Vera D Jäger; Veselin H Gyurov; John P Kowalski; Stephanie Mielke; Allan E Rettie; Helmut Hanenberg; Constanze Wiek; Marco Girhard
Journal:  Protein Eng Des Sel       Date:  2017-03-01       Impact factor: 1.650

3.  Cloning of a cDNA coding for P-450 LM3c from rabbit liver microsomes and regulation of its expression.

Authors:  C Dalet; J M Blanchard; P Guzelian; J Barwick; H Hartle; P Maurel
Journal:  Nucleic Acids Res       Date:  1986-08-11       Impact factor: 16.971

Review 4.  Role of cytochrome P-450 and related enzymes in the pulmonary metabolism of xenobiotics.

Authors:  R M Philpot; B R Smith
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

5.  Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution.

Authors:  Eva M Schmidt; Constanze Wiek; Oliver T Parkinson; Katharina Roellecke; Marcel Freund; Michael Gombert; Nadine Lottmann; Charles A Steward; Christof M Kramm; Vladimir Yarov-Yarovoy; Allan E Rettie; Helmut Hanenberg
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.